Acquiring Company
Veracyte
Acquired Company
Convergent Genomics
South San FranciscoDelawareBiotechnologyHealth CareArtificial IntelligenceGeneticsHealth DiagnosticsBiotechnologyHealth CareGeneticsHealth DiagnosticsDescription
On September 10, 2026, Veracyte, Inc. entered into a Merger Agreement with Convergent Genomics Inc. On September 14, 2026, Convergent was merged into Veracyte's wholly-owned subsidiary, Merger Sub, ceasing to exist separately. Convergent will continue as a wholly owned subsidiary of Veracyte. This acquisition aims to enhance Veracyte's genomic diagnostics portfolio.
Quick answer
Veracyte is acquiring Convergent Genomics, announced September 14, 2026. Veracyte is based in South San Francisco, California, United States.
- How much did Veracyte pay for Convergent Genomics?
- The deal value was not disclosed.
- What does Veracyte do?
- Veracyte, Inc. is a leading cancer diagnostics company specializing in transforming cancer care through high-performing tests.
- Where are Veracyte and Convergent Genomics based?
- Veracyte is based in South San Francisco, California, United States. Convergent Genomics is based in Delaware, United States.
- Who are the decision-makers at Veracyte?
- Fundz holds 4 contacts at Veracyte. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Genetics and Health Diagnostics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Cent acquires AI radiology platform Medsee (October 27, 2026)
- Dr Lal PathLabs to acquire 70% stake in SN Genelab (September 24, 2026)
- DataMEDS acquires Helomics from Axe Compute (September 15, 2026)
- Real Diagnostics acquires SimplyTest for oral health (October 22, 2026)
- Sopris Capital acquires Blackford Analysis for growth (October 9, 2026)
- Medneo UK to acquire Burgess Diagnostics (October 9, 2026)
Who to call at Veracyte, and when
When Veracyte changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Veracyte raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Veracyte, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Veracyte. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Veracyte makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Convergent Genomics?
Convergent Genomics was acquired by Veracyte, based in South San Francisco. The deal was reported on September 14, 2026. Veracyte, Inc. is a leading cancer diagnostics company specializing in transforming cancer care through high-performing tests. Veracyte is publicly traded (VCYT) and operates in Biotechnology.
When did Veracyte acquire Convergent Genomics?
Veracyte's acquisition of Convergent Genomics was reported on September 14, 2026. On September 10, 2026, Veracyte, Inc. entered into a Merger Agreement with Convergent Genomics Inc. On September 14, 2026, Convergent was merged into Veracyte's wholly-owned subsidiary, Merger Sub, ceasing to exist separately. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Convergent Genomics do?
Convergent Genomics Inc. is a biotechnology company specializing in genomic diagnostics, particularly for bladder cancer. Their focus is on developing tests that provide actionable insights to clinicians and patients. It is privately held, operating in Biotechnology, and is based in Delaware.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.